MAM
Smile Group names Gagandeep Singh Bedi to lead Healthtech venture builder in Asia
MUMBAI: Smile Group has taken a bold step into Healthtech. The tech investment and venture-building firm has named pharma industry veteran Gagandeep Singh Bedi as managing partner to lead its new Healthtech Venture Builder initiative, marking its formal foray into a space projected to hit $50 billion across APAC.
With more than 25 years of leadership experience at Astrazeneca, Boehringer Ingelheim, Eli Lilly, and Baxter, Bedi brings both gravitas and grit to the new role. At Astrazeneca India, he steered a turnaround that doubled market growth and tripled market capitalisation to $1 billion, while also contributing to India’s Covid-19 vaccine rollout.
Bedi has been actively involved in India’s startup ecosystem, leading healthcare innovation partnerships with IIT Kanpur and the India-Sweden Healthcare Innovation Centre, alongside early-stage bets in Healthtech startups focused on coronary and oncology care.
“Smile Group’s strong track record in scaling impactful, tech-forward ventures across Asia is something I’ve always deeply respected”, said Bedi. “Their unique approach—combining capital with deep operational support—resonates strongly with my focus on partnering with mission-driven startup founders”.
Smile Group founder & CEO Harish Bahl added, “With AI in healthcare becoming a $50B+ opportunity across APAC, and India’s market growing at 42 per cent annually, the pace of change in Healthtech is phenomenal. Gagandeep’s rare combination of corporate leadership and Healthtech experience makes him the ideal fit”.
The venture builder will focus on co-creating disruptive Healthtech businesses across Asia by combining Smile’s capital firepower and founder-first model with Bedi’s domain expertise and deep ecosystem connects.
Brands
Safex Group appoints Richa Malhotra as group chief financial officer
Former Standard Chartered executive to steer finance
NEW DELHI: Safex Chemicals has appointed Richa Malhotra as group chief financial officer, strengthening its leadership team as the company prepares for the next phase of expansion in specialty chemicals and global agrochemicals.
In her new role, Malhotra will lead the group’s financial strategy, capital architecture and governance framework as Safex scales operations across multiple verticals including branded formulations, specialty chemicals and contract manufacturing.
A chartered accountant and graduate of Shri Ram College of Commerce, University of Delhi, Malhotra brings more than two decades of experience in business finance, strategic planning, corporate banking and client management.
Before joining Safex, she served as executive director, financial markets at Standard Chartered, where she led teams across India and Sri Lanka and worked closely with large corporates, global subsidiaries and commercial banking clients. Her expertise includes capital structuring, treasury operations, risk management and financial markets led financing solutions.
Safex Group promoter director and joint managing director Piyush Jindal, said the appointment comes at a pivotal time for the company. “Safex stands at an inflection point as we build an integrated platform across branded formulations, specialty chemicals and contract manufacturing. Richa’s experience across global financial institutions will strengthen our financial discipline and help unlock value across the group,” he said.
Malhotra said she was looking forward to contributing to the company’s next chapter of growth. “Safex has built a strong reputation over 35 years with its focus on integrity, innovation and agricultural insight. I am excited to be part of the organisation as it expands its footprint in India and global markets,” she said.
The appointment comes as Safex continues to strengthen its financial foundations and scale operations internationally, positioning itself for future growth milestones.
